香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易 向白雲山生物增資 本次增資 於2025年5月28日，董事會批准本公司訂立增資協議。根據該協議，本公司、廣藥創投基金、 廣州老字號基金分別向白雲山生物增資人民幣15,000.00萬元、人民幣13,000.00萬元和人民幣 2,000.00萬元，白雲山生物的其他股東將放棄就本次增資行使其優先認購權。本次增資完成後， 白雲山生物的註冊資本將由人民幣8,400.00萬元增加至人民幣12,053.5909萬元。本公司於白雲山 生物的直接及間接持股比例將維持不變，仍為50.00%。白雲山生物仍為本公司之附屬公司，其財 務業績繼續納入本公司之合併報表。 截至本公告日期，增資協議尚未正式簽署。本公司將根據香港上市規則之規定於增資協議簽署後 另行刊發公告。本公司股東及潛在投資者於買賣本公司股份時，務請審慎行事。 香港上市規則的涵義 於本公告日期，本公司之控股股東廣藥集團間接控制廣藥產投基金，廣藥產投基金因此為本 ...

证券代码：600332 证券简称：白云山 公告编号：2025－043 广州白云山医药集团股份有限公司 表决结果：同意票 8 票、反对票 0 票、弃权票 0 票，审议通过本议案。 二、关于本公司子公司广州白云山汉方现代药业有限公司实施混合所有制 改革的议案 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第二十四次 "会议"）通知于 2025 年 5 月 23 日以书面及电邮方式发出，于 2025 年 5 会议（ 月 28 日以通讯表决的方式召开。本次会议应参加表决董事 8 人，实际参加表决 董事 8 人，有效表决权人数 8 人。会议的召集、召开符合《公司法》及《公司 章程》的规定。 经董事审议、表决，会议审议通过如下议案： 一、本公司 2025 年度"提质增效重回报"行动方案（有关内容详见本公司 日期为 2025 年 5 月 28 日、编号为 2025-044 的公告） 第九届董事会第二十四次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内 表决结果：同意票 8 票、反对票 0 票、弃权票 0 票，审议通 ...

规格：每瓶装 20ml 通知书编号：2025B02220 受理号：CYZB2500430 证券代码：600332 证券简称：白云山 公告编号：2025－045 广州白云山医药集团股份有限公司 关于分公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（"本公司"）分公司广州 白云山医药集团股份有限公司白云山何济公制药厂（"何济公制药厂"） 收到国家药品监督管理局（"国家药监局"）签发的《药品补充申请批准 通知书》。现将有关情况公告如下： 一、药品的基本情况 药品通用名称：口洁喷雾剂 剂型：喷雾剂 二、药品的其他相关信息 何济公制药厂于2025 年 3 月7 日向国家药监局递交本药品补充申请， 于 2025 年 3 月 11 日获得受理。申请变更口洁喷雾剂说明书安全性信息， 包括【不良反应】、【禁忌】、【注意事项】内容。 口洁喷雾剂，用于口舌生疮，牙龈、咽喉肿痛。 截至本公告日，何济公制药厂在口洁喷雾剂研发项目上已投入研发费 用合计约人民币 64 万元（未审计）。根 ...

证券代码：600332 证券简称：白云山 公告编号：2025－044 1 广州白云山医药集团股份有限公司 2025 年度"提质增效重回报"行动方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻中央金融工作会议精神，积极响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，践行"以投资者 为本"的理念，提升投资者获得感，持续推进上市公司高质量发展，广 州白云山医药集团股份有限公司（"本公司"或"公司"）制定了 2025 年度"提质增效重回报"行动方案，具体如下： 一、聚焦主责主业，夯实产业链条，努力提升经营质量和效益 公司一直专注于医药健康产业，经过多年精心打造和高质量发展， 基本实现生物医药健康产业的全产业链布局，是全国最大的医药制造企 业集团之一。凭借深厚的历史底蕴、丰富的产业资源、完善的全产业链 布局、强大的品牌矩阵和持续创新的研发能力，公司稳居行业头部地位。 2025年，公司将继续围绕生物医药健康的战略定位，立足产业优势， 充分挖掘和盘活自身资源和资产，围绕医药制造与研发这一核心开展延 ...

一、本公司 2025 年度"提质增效重回报"行动方案（有关内容详见本公司 日期为 2025 年 5 月 28 日、编号为 2025-044 的公告） 证券代码：600332 证券简称：白云山 公告编号：2025－043 广州白云山医药集团股份有限公司 第九届董事会第二十四次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第二十四次 会议（"会议"）通知于 2025 年 5 月 23 日以书面及电邮方式发出，于 2025 年 5 月 28 日以通讯表决的方式召开。本次会议应参加表决董事 8 人，实际参加表决 董事 8 人，有效表决权人数 8 人。会议的召集、召开符合《公司法》及《公司 章程》的规定。 经董事审议、表决，会议审议通过如下议案： 广州白云山医药集团股份有限公司董事会 2025 年 5 月 28 日 2 表决结果：同意票 8 票、反对票 0 票、弃权票 0 票，审议通过本议案。 二、关于本公司子公司广州白云山汉方现代药业有限公司实施混合所有制 改革的 ...

Group 1 - The company announced a capital increase agreement approved by the board on May 28, 2025, involving investments of RMB 150 million, RMB 130 million, and RMB 20 million from the company, Guangzhou Pharmaceutical Venture Capital Fund, and Guangzhou Old Brand Fund respectively [1] - After the capital increase, the registered capital of Baiyunshan Biological will rise from RMB 84 million to RMB 121 million, while the company's direct and indirect shareholding will remain unchanged at 50% [1] - Baiyunshan Biological is a significant subsidiary of the company, primarily engaged in the research, production, and sales of human rabies vaccines (Vero cells), which is crucial for the company's innovation-driven development strategy [2] Group 2 - The capital increase aims to address the funding needs of Baiyunshan Biological, facilitating the application for production licenses for new products and supporting the development of the company's biopharmaceutical business [2] - Baiyunshan Biological's financial performance will continue to be included in the company's consolidated financial statements [1][2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：00874） 須予披露的交易：出售應收賬款 本次交易 於2025年5月28日，廣州醫藥與興證資管根據基礎資產買賣協議（第四期）簽訂《新增基礎資產交割 確認函》，確認向興證資管出售第三次新增基礎資產，並收到購買價款人民幣401,493,434.77元。 上市規則的含義 然而，根據上市規則第14.22條，如一連串交易全部均於12個月內完成或屬彼此相關者，則該等交 易應合併計算，並視作一項交易處理。鑒於本次交易及過往交易均由廣州醫藥與興證資管於12個 月內訂立，並且交易性質相似，就計算相關百分比率而言，該等交易應根據上市規則第14.22條進 行合併。 由於根據上市規則第14.07條就本次交易及過往交易按合併基準計算的最高適用百分比率高於5% 但低於25%，因此，本次交易構成本公司在上市規則第14章下的須予披露的交易，須遵守上市規 則下的申報及公告規定 ...

Group 1 - The "bottle-to-electric" policy is transforming traditional cooking methods in Guangdong, with many businesses adopting electric cooking appliances for safety and cost efficiency [1][2] - In the first four months of 2025, Guangdong's power grid achieved an electricity substitution of 150.16 billion kilowatt-hours, resulting in a CO2 reduction of 1,497,130 tons, equivalent to planting 818 million trees [1] - The "bottle-to-electric" initiative is supported by a one-stop electricity service, including installation and after-sales support, to facilitate the transition for users [2] Group 2 - As of May 20, 2023, Guangdong's power grid operates 16,242 charging piles across 1,033 towns, enhancing the accessibility of electric vehicles in rural areas [3] - The Guangdong power grid is promoting energy-efficient and low-carbon equipment across various industries, including agriculture and manufacturing, to improve operational efficiency and reduce costs [4][5] - The goal for the year is to achieve an electricity substitution of no less than 410 billion kilowatt-hours, supporting high-quality economic development in Guangdong [6]

Core Insights - The health nutrition industry is undergoing structural transformation due to heightened health awareness, stricter regulations, and a return to rational consumption, leading brands to adjust pricing, optimize inventory, and focus on channel and profit model reconstruction [1][2]. Industry Overview - The health nutrition industry is entering a high-quality development phase in 2024, driven by policy, economic, capital, and technological synergies [10]. - Regulatory bodies are enhancing the registration and filing standards for health nutrition products, increasing oversight across production and sales [11]. Product Category Situation - The industry is focusing on four core consumer groups: middle-aged working individuals, high-net-worth individuals, rehabilitation needs, and the elderly [52]. - Key product categories gaining attention include immune enhancement, joint and bone care, and probiotics, while categories like anti-aging are experiencing a decline [54][56]. Financing Trends - In 2024, the number of financing events in the health nutrition industry decreased, but the total financing amount increased, with upstream companies, particularly probiotic suppliers, being favored by investors [16][17]. - The financing amount rose by 3.21 billion yuan despite a reduction in the number of financing events [18]. Sales Channel Dynamics - Private domain e-commerce has surpassed traditional pharmaceutical chains for the first time, with platforms like Douyin Global Purchase emerging as significant players in the cross-border B2C market [2][30]. - Retailers are increasingly adopting a "direct procurement" model, with over 25% of retailers sourcing products directly from manufacturers [31]. Strategic Adjustments - In response to market pressures, 60% of small and medium-sized enterprises are reducing R&D investments and shifting towards OEM models to maintain cash flow [27]. - Major brands are enhancing their channel, product, and marketing strategies, focusing on dual strategies of high-end and affordable products [26]. Consumer Preferences - The average transaction price for core products in the health nutrition sector has significantly decreased, with 31% of companies reporting prices in the 50-100 yuan range in 2024, up 17.22% from 2023 [14][15]. - The demand for personalized and functional health products is rising, particularly among younger consumers and new parents [81][84]. Future Outlook - By 2025, nearly 42% of companies anticipate that tightening policies and consumer downgrade will hinder rapid growth in the industry [35]. - Brands are expected to shift their focus towards value-driven strategies, including price adjustments and new channel explorations, to sustain growth [37][41].

Core Viewpoint - The article emphasizes the increasing prevalence of stroke among the population aged 40 and above in China, highlighting the importance of early detection, intervention, and treatment to mitigate the risks associated with stroke [1][2]. Group 1: Stroke Statistics and Risk Factors - As of 2023, there are 12.42 million stroke patients aged 40 and above in China, with one person experiencing a stroke every 10 seconds and one person dying from a stroke every 28 seconds [1]. - The top three risk factors for stroke are hypertension (35.62%), dyslipidemia (34.71%), and smoking (31.37%), with physical inactivity at 27.83% [1]. - Common lifestyle habits such as being overweight, staying up late, and consuming a high-fat diet are contributing to the younger onset of stroke [1]. Group 2: Prevention and Awareness Initiatives - In response to the "early detection, early intervention, early treatment" philosophy, a public awareness campaign was held on May 24, 2023, by Guangzhou Baiyunshan Zhongyi Pharmaceutical and Baiyunshan Qixing Pharmaceutical, along with various chain pharmacies across multiple cities [1]. - The campaign aims to educate the public about stroke risks and promote early screening and intervention strategies [3]. Group 3: Medical Insights and Recommendations - Medical professionals stress the importance of recognizing warning signs of stroke, such as facial drooping, sudden speech difficulties, and unilateral weakness [2]. - Immediate action, such as calling emergency services within 4.5 hours of symptoms, is crucial for effective treatment [2]. - Regular monitoring of health indicators for individuals with hypertension, diabetes, and dyslipidemia is recommended, along with lifestyle modifications like smoking cessation and weight control [2][3].